<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="topic" /><meta name="keywords" content="Ulcerative colitis; Colitis: ulcerative; Crohn’s disease; Aminosalicylates; Balsalazide; Mesalazine; Olsalazine; Sulfasalazine; Corticosteroids: inflammatory bowel disease; Budesonide: inflammatory bowel disease; Budesonide: Crohn’s; Beclometasone dipropionate: ulcerative colitis; Ciclosporin: ulcerative colitis; Mercaptopurine: inflammatory bowel disease; Methotrexate: Crohn’s disease; Infliximab: Crohn’s disease; Infliximab: ulcerative colitis; Adalimumab: Crohn’s disease; Azathioprine: inflammatory bowel disease; Crohn’s disease: fistulating; Metronidazole: Crohn’s disease; Ciprofloxacin: Crohn’s disease; Azathioprine: inflammatory bowel disease; Mercaptopurine: inflammatory bowel disease; Infliximab: Crohn’s disease; Adalimumab: Crohn’s disease" /><meta name="IX" content="Ulcerative colitis; Colitis: ulcerative; Crohn’s disease; Aminosalicylates; Balsalazide; Mesalazine; Olsalazine; Sulfasalazine; Corticosteroids: inflammatory bowel disease; Budesonide: inflammatory bowel disease; Budesonide: Crohn’s; Beclometasone dipropionate: ulcerative colitis; Ciclosporin: ulcerative colitis; Mercaptopurine: inflammatory bowel disease; Methotrexate: Crohn’s disease; Infliximab: Crohn’s disease; Infliximab: ulcerative colitis; Adalimumab: Crohn’s disease; Azathioprine: inflammatory bowel disease; Crohn’s disease: fistulating; Metronidazole: Crohn’s disease; Ciprofloxacin: Crohn’s disease; Azathioprine: inflammatory bowel disease; Mercaptopurine: inflammatory bowel disease; Infliximab: Crohn’s disease; Adalimumab: Crohn’s disease" /><title>Inflammatory bowel disease: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="100022.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="100022.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=100022.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="1001.htm">1 Gastro-intestinal system</a> &gt; <a href="2164.htm">1.5 Chronic bowel disorders</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="2164.htm" title="Previous: 1.5 Chronic bowel disorders">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="100023.htm" title="Next: Clostridium difficile infection">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_100022">Inflammatory bowel disease</h1><?highlighter on?><div id="pC" class="jN"><p>Chronic inflammatory bowel diseases include <i>ulcerative colitis</i> and <i>Crohn’s disease</i>. Effective management
requires drug therapy, attention to nutrition, and in severe or chronic
active disease, surgery. </p><p><b>Aminosalicylates</b> (balsalazide, <span>mesalazine</span>, olsalazine, and <span>sulfasalazine</span>), <b><span>corticosteroids</span></b> (<span>hydrocortisone</span>, beclometasone, <span>budesonide</span>, and <span>prednisolone</span>), and <b>drugs that affect
the immune response</b> are used in the treatment of inflammatory
bowel disease.</p><div class="cAZ" id="_209092"><h2>Treatment of acute ulcerative colitis and Crohn’s disease</h2> <p class="cAX">Acute mild to moderate disease affecting the rectum (proctitis)
or the recto-sigmoid is treated initially with local application of
an aminosalicylate (<a title="BNF:sub-section: Aminosalicylates" href="201289.htm#_201289">section 1.5.1</a>); alternatively, a local corticosteroid
can be used but it is less effective. A combination of a local aminosalicylate
and a local corticosteroid can be used for proctitis that does not
respond to a local aminosalicylate alone. Foam preparations and suppositories
are especially useful when patients have difficulty retaining liquid
enemas.</p><p>Diffuse inflammatory bowel disease or disease that does not
respond to local therapy requires oral treatment. Mild disease affecting
the proximal colon can be treated with an oral aminosalicylate alone;
a combination of a local and an oral aminosalicylate can be used in
proctitis or distal colitis. Refractory or moderate inflammatory bowel
disease usually requires adjunctive use of an oral corticosteroid
such as <b><span>prednisolone</span></b> (<a title="BNF:monograph: PREDNISOLONE" href="2181.htm#_2181">section 1.5.2</a>) for 4–8 weeks. Modified-release <b><span>budesonide</span></b> is licensed for Crohn’s disease
affecting the ileum and the ascending colon; it causes fewer systemic
side-effects than oral <span>prednisolone</span> but may be
less effective. <b>Beclometasone dipropionate</b> by
mouth is licensed as an adjunct to mesalazine for mild to moderate
ulcerative colitis, but it is not known whether it is as effective
as other corticosteroids.</p><p>Severe inflammatory bowel disease or disease that is not responding
to an oral corticosteroid requires hospital admission and treatment
with an intravenous corticosteroid (such as <a title="monograph: HYDROCORTISONE" href="4276.htm#_4276">hydrocortisone</a> or <a title="monograph: METHYLPREDNISOLONE" href="4284.htm#_4284">methylprednisolone</a>); other therapy may include intravenous
fluid and electrolyte replacement, and possibly parenteral nutrition.
Specialist supervision is required for patients who fail to respond
adequately to these measures. Patients with severe ulcerative colitis
that has not responded to intravenous corticosteroids, may benefit
from a short course of intravenous <span><b>ciclosporin</b></span> [unlicensed indication] (<a title="BNF:monograph: CICLOSPORIN" href="201296.htm#_201296">section 1.5.3</a>). Patients with unresponsive
or chronically active Crohn’s disease may benefit from <b>azathioprine</b> (<a title="BNF:monograph: AZATHIOPRINE" href="201293.htm#_201293">section 1.5.3</a>), <b>mercaptopurine</b> (<a title="BNF:monograph: MERCAPTOPURINE" href="201298.htm#_201298">section 1.5.3</a>), or once-weekly <b>methotrexate</b> (<a title="BNF:monograph: METHOTREXATE" href="201304.htm#_201304">section 1.5.3</a>) [all unlicensed indications];
these drugs have a slower onset of action.</p><p><b><span>Infliximab</span></b> (<a title="BNF:monograph: INFLIXIMAB" href="128211.htm#_128211">section 1.5.3</a>) is licensed for the management
of severe active Crohn’s disease and severe ulcerative colitis in
patients whose condition has not responded adequately to treatment
with a corticosteroid and a conventional drug that affects the immune
response, or who are intolerant of them.</p><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Infliximab and adalimumab for Crohn’s disease (May
2010)</h3><p>Infliximab or adalimumab is recommended for the treatment of
severe active Crohn’s disease that has not responded to conventional
therapy (including corticosteroids and other drugs affecting the immune
response) or when conventional therapy cannot be used because of intolerance
or contra-indications; infliximab can also be used in a similar way
in children over 6 years of age. In adults over 18 years of age, infliximab
is recommended for the treatment of fistulating Crohn’s disease that
has not responded to conventional therapy (including antibacterials,
drainage, and other drugs affecting the immune response) or when conventional
therapy cannot be used because of intolerance or contra-indications.</p><p>Infliximab or adalimumab should be given as a planned course
of treatment for 12 months or until treatment failure, whichever is
shorter. Treatment should be continued beyond 12 months only if there
is evidence of active disease—in these cases the need for treatment
should be reviewed at least annually. If the disease relapses after
stopping treatment, adalimumab or infliximab can be restarted [but
see <a title="BNF:monograph: INFLIXIMAB" href="128211.htm#_128211">Hypersensitivity Reactions</a> under Infliximab].</p></div><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Infliximab for subacute manifestations of ulcerative
colitis (April 2008)</h3><p>Infliximab is <b>not</b> recommended for the treatment
of subacute manifestations of moderate to severe active ulcerative
colitis that would normally be managed in an outpatient setting.</p></div><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Infliximab for acute exacerbations of ulcerative
colitis (December 2008)</h3><p>Infliximab is recommended as an option for the treatment of
acute exacerbations of severe ulcerative colitis when treatment with
ciclosporin is contra-indicated or inappropriate.</p></div><div id="_200354"> <p class="cAX"><b>Adalimumab</b> (<a title="BNF:monograph: ADALIMUMAB" href="200265.htm#_200265">section 1.5.3</a>) is licensed for the treatment
of severe active Crohn’s disease in patients whose condition has not
responded adequately to treatment with a corticosteroid and a conventional
drug that affects the immune response, or who are intolerant of them.
For inducing remission, adalimumab should be used in combination with
a corticosteroid, but it may be given alone if a corticosteroid is
inappropriate or is not tolerated. Adalimumab may also be used for
Crohn’s disease in patients who have relapsed while taking infliximab
or who cannot tolerate infliximab because of hypersensitivity reactions.</p></div></div><div class="cAZ"><h2>Maintenance of remission of acute ulcerative colitis and Crohn’s
disease</h2> <p class="cAX">Smoking cessation (<a title="BNF:sub-section: Cigarette smoking" href="3689.htm#_3689">section 4.10.2</a>) reduces the risk of relapse
in Crohn’s disease and should be encouraged. <b>Aminosalicylates</b> are efficacious in the maintenance of remission of ulcerative colitis,
but there is no evidence of efficacy in the maintenance of remission
of Crohn’s disease. <span>Corticosteroids</span> are <b>not</b> suitable for maintenance treatment because of their
side-effects. In resistant or frequently relapsing cases either <b><span>azathioprine</span></b> (<a title="BNF:monograph: AZATHIOPRINE" href="201293.htm#_201293">section 1.5.3</a>) [unlicensed indication] or <b><span>mercaptopurine</span></b> (<a title="BNF:monograph: MERCAPTOPURINE" href="201298.htm#_201298">section 1.5.3</a>) [unlicensed indication], given
under close supervision may be helpful. Methotrexate (<a title="BNF:monograph: METHOTREXATE" href="201304.htm#_201304">section 1.5.3</a>) is tried in Crohn’s disease
if azathioprine or mercaptopurine cannot be used [unlicensed indication].
Maintenance therapy with infliximab should be considered for patients
with Crohn’s disease or ulcerative colitis who respond to the initial
induction course of infliximab; fixed-interval dosing is superior
to intermittent dosing. <b>Adalimumab</b> is licensed for
maintenance therapy in Crohn’s disease.</p></div><div id="_200260"><div class="cAZ"><h2>Fistulating Crohn’s disease</h2> <p class="cAX">Treatment may not be necessary for
simple, asymptomatic perianal fistulas. <b><span>Metronidazole</span></b> (<a title="monograph: METRONIDAZOLE" href="3932.htm#_3932">section 5.1.11</a>) or <b>ciprofloxacin</b> (<a title="monograph: CIPROFLOXACIN" href="3945.htm#_3945">section 5.1.12</a>) can improve symptoms of fistulating Crohn’s
disease but complete healing occurs rarely [unlicensed indication].
Metronidazole by mouth is used at a dose of 10–20 mg/kg daily in divided
doses (usual dose 400–500 mg 3 times daily); it is usually given for
1 month but no longer than 3 months because of concerns about peripheral
neuropathy. Ciprofloxacin by mouth is given at a dose of 500 mg twice
daily. Other antibacterials should be given if specifically indicated
(e.g. sepsis associated with fistulas and perianal disease) and for
managing bacterial overgrowth in the small bowel. Fistulas may also
require surgical exploration and local drainage.</p><p>Either <b>azathioprine</b> or <b>mercaptopurine</b> is used
as a second-line treatment for fistulating Crohn’s disease and continued
for maintenance [unlicensed indication]. <b>Infliximab</b> is used for fistulating
Crohn’s disease refractory to conventional treatments; fixed-interval
dosing is superior to intermittent dosing. Maintenance therapy with
infliximab should be considered for patients who respond to the initial
induction course of infliximab. <b>Adalimumab</b> can be used if there is intolerance to
infliximab [unlicensed indication]</p></div></div><div class="cAZ"><h2>Adjunctive treatment of inflammatory bowel disease</h2> <p class="cAX">Due attention should be paid to diet; high-fibre or low-residue diets
should be used as appropriate.</p><p>Antimotility drugs such as codeine and loperamide, and antispasmodic
drugs may precipitate paralytic ileus and megacolon in active ulcerative
colitis; treatment of the inflammation is more logical. Laxatives
may be required in proctitis. Diarrhoea resulting from the loss of
bile-salt absorption (e.g. in terminal ileal disease or bowel resection)
may improve with <b><span>colestyramine</span></b> (<a title=" Bile acid sequestrants" href="2294.htm#_2294">section 1.9.2</a>), which binds bile salts.</p></div></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="2164.htm">Previous: 1.5 Chronic bowel disorders</a> | <a class="top" href="100022.htm#">Top</a> | <a accesskey="]" href="100023.htm">Next: <span class="cAC">Clostridium difficile</span> infection</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>